Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV
To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV. Cross-sectional study. We enrolled adults living with HIV who were IPT-naive or had completed IPT...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2022-08, Vol.36 (10), p.1363-1371 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1371 |
|---|---|
| container_issue | 10 |
| container_start_page | 1363 |
| container_title | AIDS (London) |
| container_volume | 36 |
| creator | Valinetz, Ethan D. Matemo, Daniel Gersh, Jill K. Joudeh, Lara L. Mendelsohn, Simon C. Scriba, Thomas J. Hatherill, Mark Kinuthia, John Wald, Anna Cangelosi, Gerard A. Barnabas, Ruanne V. Hawn, Thomas R. Horne, David J. |
| description | To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV.
Cross-sectional study.
We enrolled adults living with HIV who were IPT-naive or had completed IPT more than 6 months prior at HIV care clinics in western Kenya. We calculated TB signatures using gene expression data from qRT-PCR. We used multivariable linear regression to analyze the association between prior receipt of IPT or NTM sputum culture positivity with a transcriptional TB risk score, RISK6 (range 0-1). In secondary analyses, we explored the association between IPT or NTM positivity and four other TB transcriptional signatures.
Among 381 participants, 99.7% were receiving antiretroviral therapy and 86.6% had received IPT (completed median of 1.1 years prior). RISK6 scores were lower (mean difference 0.10; 95% confidence interval (CI): 0.06-0.15; P |
| doi_str_mv | 10.1097/QAD.0000000000003262 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_wolte</sourceid><recordid>TN_cdi_pubmed_primary_35608118</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35608118</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3075-b8e45757b1e9000d053822a683c126dde5f85a87bd3c9f143891f507ecfd9e4b3</originalsourceid><addsrcrecordid>eNpNkF9LwzAUxYMobk6_gUi-QOdN0jTp45h_NhiIoL74UNL21ka7tiTpxvz0bkzB83Lg8ONw7yHkmsGUQapun2d3U_gnwRN-QsYsViKSUrFTMgaepFEqFIzIhfefe0iC1udkJGQCmjE9Ju9L37XWfNuS9g432Aa7QRpqdKbfUdOWNAw5umJoOm89Dc60vnC2D7ZrTUO9_WhNGBx6alvaY9c3SLc21HSxfLskZ5VpPF79-oS8Pty_zBfR6ulxOZ-tokKAklGuMZZKqpxhuj-xBCk05ybRomA8KUuUlZZGq7wURVqxWOiUVRIUFlWZYpyLCbk59vZDvsYy651dG7fL_r7cA_ER2HZNQOe_mmGLLqvRNKHODuNxEBBx4Bw0MIgOkRQ_VYdmDw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Valinetz, Ethan D. ; Matemo, Daniel ; Gersh, Jill K. ; Joudeh, Lara L. ; Mendelsohn, Simon C. ; Scriba, Thomas J. ; Hatherill, Mark ; Kinuthia, John ; Wald, Anna ; Cangelosi, Gerard A. ; Barnabas, Ruanne V. ; Hawn, Thomas R. ; Horne, David J.</creator><creatorcontrib>Valinetz, Ethan D. ; Matemo, Daniel ; Gersh, Jill K. ; Joudeh, Lara L. ; Mendelsohn, Simon C. ; Scriba, Thomas J. ; Hatherill, Mark ; Kinuthia, John ; Wald, Anna ; Cangelosi, Gerard A. ; Barnabas, Ruanne V. ; Hawn, Thomas R. ; Horne, David J.</creatorcontrib><description>To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV.
Cross-sectional study.
We enrolled adults living with HIV who were IPT-naive or had completed IPT more than 6 months prior at HIV care clinics in western Kenya. We calculated TB signatures using gene expression data from qRT-PCR. We used multivariable linear regression to analyze the association between prior receipt of IPT or NTM sputum culture positivity with a transcriptional TB risk score, RISK6 (range 0-1). In secondary analyses, we explored the association between IPT or NTM positivity and four other TB transcriptional signatures.
Among 381 participants, 99.7% were receiving antiretroviral therapy and 86.6% had received IPT (completed median of 1.1 years prior). RISK6 scores were lower (mean difference 0.10; 95% confidence interval (CI): 0.06-0.15; P < 0.001) among participants who received IPT than those who did not. In a model that adjusted for age, sex, duration of ART, and plasma HIV RNA, the RISK6 score was 52.8% lower in those with a history of IPT ( P < 0.001). No significant association between year of IPT receipt and RISK6 scores was detected. There was no association between NTM sputum culture positivity and RISK6 scores.
In people with HIV, IPT was associated with significantly lower RISK6 scores compared with persons who did not receive IPT. These data support investigations of its performance as a TB preventive therapy response biomarker.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0000000000003262</identifier><identifier>PMID: 35608118</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins</publisher><subject>Adult ; Antitubercular Agents - therapeutic use ; Cross-Sectional Studies ; HIV Infections - complications ; HIV Infections - drug therapy ; Humans ; Isoniazid - therapeutic use ; Tuberculosis - complications</subject><ispartof>AIDS (London), 2022-08, Vol.36 (10), p.1363-1371</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3075-b8e45757b1e9000d053822a683c126dde5f85a87bd3c9f143891f507ecfd9e4b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35608118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valinetz, Ethan D.</creatorcontrib><creatorcontrib>Matemo, Daniel</creatorcontrib><creatorcontrib>Gersh, Jill K.</creatorcontrib><creatorcontrib>Joudeh, Lara L.</creatorcontrib><creatorcontrib>Mendelsohn, Simon C.</creatorcontrib><creatorcontrib>Scriba, Thomas J.</creatorcontrib><creatorcontrib>Hatherill, Mark</creatorcontrib><creatorcontrib>Kinuthia, John</creatorcontrib><creatorcontrib>Wald, Anna</creatorcontrib><creatorcontrib>Cangelosi, Gerard A.</creatorcontrib><creatorcontrib>Barnabas, Ruanne V.</creatorcontrib><creatorcontrib>Hawn, Thomas R.</creatorcontrib><creatorcontrib>Horne, David J.</creatorcontrib><title>Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV.
Cross-sectional study.
We enrolled adults living with HIV who were IPT-naive or had completed IPT more than 6 months prior at HIV care clinics in western Kenya. We calculated TB signatures using gene expression data from qRT-PCR. We used multivariable linear regression to analyze the association between prior receipt of IPT or NTM sputum culture positivity with a transcriptional TB risk score, RISK6 (range 0-1). In secondary analyses, we explored the association between IPT or NTM positivity and four other TB transcriptional signatures.
Among 381 participants, 99.7% were receiving antiretroviral therapy and 86.6% had received IPT (completed median of 1.1 years prior). RISK6 scores were lower (mean difference 0.10; 95% confidence interval (CI): 0.06-0.15; P < 0.001) among participants who received IPT than those who did not. In a model that adjusted for age, sex, duration of ART, and plasma HIV RNA, the RISK6 score was 52.8% lower in those with a history of IPT ( P < 0.001). No significant association between year of IPT receipt and RISK6 scores was detected. There was no association between NTM sputum culture positivity and RISK6 scores.
In people with HIV, IPT was associated with significantly lower RISK6 scores compared with persons who did not receive IPT. These data support investigations of its performance as a TB preventive therapy response biomarker.</description><subject>Adult</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Cross-Sectional Studies</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Humans</subject><subject>Isoniazid - therapeutic use</subject><subject>Tuberculosis - complications</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkF9LwzAUxYMobk6_gUi-QOdN0jTp45h_NhiIoL74UNL21ka7tiTpxvz0bkzB83Lg8ONw7yHkmsGUQapun2d3U_gnwRN-QsYsViKSUrFTMgaepFEqFIzIhfefe0iC1udkJGQCmjE9Ju9L37XWfNuS9g432Aa7QRpqdKbfUdOWNAw5umJoOm89Dc60vnC2D7ZrTUO9_WhNGBx6alvaY9c3SLc21HSxfLskZ5VpPF79-oS8Pty_zBfR6ulxOZ-tokKAklGuMZZKqpxhuj-xBCk05ybRomA8KUuUlZZGq7wURVqxWOiUVRIUFlWZYpyLCbk59vZDvsYy651dG7fL_r7cA_ER2HZNQOe_mmGLLqvRNKHODuNxEBBx4Bw0MIgOkRQ_VYdmDw</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Valinetz, Ethan D.</creator><creator>Matemo, Daniel</creator><creator>Gersh, Jill K.</creator><creator>Joudeh, Lara L.</creator><creator>Mendelsohn, Simon C.</creator><creator>Scriba, Thomas J.</creator><creator>Hatherill, Mark</creator><creator>Kinuthia, John</creator><creator>Wald, Anna</creator><creator>Cangelosi, Gerard A.</creator><creator>Barnabas, Ruanne V.</creator><creator>Hawn, Thomas R.</creator><creator>Horne, David J.</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20220801</creationdate><title>Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV</title><author>Valinetz, Ethan D. ; Matemo, Daniel ; Gersh, Jill K. ; Joudeh, Lara L. ; Mendelsohn, Simon C. ; Scriba, Thomas J. ; Hatherill, Mark ; Kinuthia, John ; Wald, Anna ; Cangelosi, Gerard A. ; Barnabas, Ruanne V. ; Hawn, Thomas R. ; Horne, David J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3075-b8e45757b1e9000d053822a683c126dde5f85a87bd3c9f143891f507ecfd9e4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Cross-Sectional Studies</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Humans</topic><topic>Isoniazid - therapeutic use</topic><topic>Tuberculosis - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valinetz, Ethan D.</creatorcontrib><creatorcontrib>Matemo, Daniel</creatorcontrib><creatorcontrib>Gersh, Jill K.</creatorcontrib><creatorcontrib>Joudeh, Lara L.</creatorcontrib><creatorcontrib>Mendelsohn, Simon C.</creatorcontrib><creatorcontrib>Scriba, Thomas J.</creatorcontrib><creatorcontrib>Hatherill, Mark</creatorcontrib><creatorcontrib>Kinuthia, John</creatorcontrib><creatorcontrib>Wald, Anna</creatorcontrib><creatorcontrib>Cangelosi, Gerard A.</creatorcontrib><creatorcontrib>Barnabas, Ruanne V.</creatorcontrib><creatorcontrib>Hawn, Thomas R.</creatorcontrib><creatorcontrib>Horne, David J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valinetz, Ethan D.</au><au>Matemo, Daniel</au><au>Gersh, Jill K.</au><au>Joudeh, Lara L.</au><au>Mendelsohn, Simon C.</au><au>Scriba, Thomas J.</au><au>Hatherill, Mark</au><au>Kinuthia, John</au><au>Wald, Anna</au><au>Cangelosi, Gerard A.</au><au>Barnabas, Ruanne V.</au><au>Hawn, Thomas R.</au><au>Horne, David J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>36</volume><issue>10</issue><spage>1363</spage><epage>1371</epage><pages>1363-1371</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV.
Cross-sectional study.
We enrolled adults living with HIV who were IPT-naive or had completed IPT more than 6 months prior at HIV care clinics in western Kenya. We calculated TB signatures using gene expression data from qRT-PCR. We used multivariable linear regression to analyze the association between prior receipt of IPT or NTM sputum culture positivity with a transcriptional TB risk score, RISK6 (range 0-1). In secondary analyses, we explored the association between IPT or NTM positivity and four other TB transcriptional signatures.
Among 381 participants, 99.7% were receiving antiretroviral therapy and 86.6% had received IPT (completed median of 1.1 years prior). RISK6 scores were lower (mean difference 0.10; 95% confidence interval (CI): 0.06-0.15; P < 0.001) among participants who received IPT than those who did not. In a model that adjusted for age, sex, duration of ART, and plasma HIV RNA, the RISK6 score was 52.8% lower in those with a history of IPT ( P < 0.001). No significant association between year of IPT receipt and RISK6 scores was detected. There was no association between NTM sputum culture positivity and RISK6 scores.
In people with HIV, IPT was associated with significantly lower RISK6 scores compared with persons who did not receive IPT. These data support investigations of its performance as a TB preventive therapy response biomarker.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins</pub><pmid>35608118</pmid><doi>10.1097/QAD.0000000000003262</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2022-08, Vol.36 (10), p.1363-1371 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_pubmed_primary_35608118 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Antitubercular Agents - therapeutic use Cross-Sectional Studies HIV Infections - complications HIV Infections - drug therapy Humans Isoniazid - therapeutic use Tuberculosis - complications |
| title | Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A24%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_wolte&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isoniazid%20preventive%20therapy%20and%20tuberculosis%20transcriptional%20signatures%20in%20people%20with%20HIV&rft.jtitle=AIDS%20(London)&rft.au=Valinetz,%20Ethan%20D.&rft.date=2022-08-01&rft.volume=36&rft.issue=10&rft.spage=1363&rft.epage=1371&rft.pages=1363-1371&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0000000000003262&rft_dat=%3Cpubmed_wolte%3E35608118%3C/pubmed_wolte%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35608118&rfr_iscdi=true |